Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026

Immix Biopharma (Nasdaq: IMMX) will present interim NXC-201 trial results at the American Society of Hematology meeting on December 14, 2026.

Rhea-AI Summary

Immix Biopharma (Nasdaq: IMMX) will present interim NXC-201 trial results at the American Society of Hematology meeting on December 14, 2026.

The oral presentation covers 45-patient safety and efficacy data from NEXICART-2, a U.S. trial in relapsed or refractory AL amyloidosis. Presentation #826 is scheduled for 11:15 AM Central Time at the meeting in New Orleans. The announcement provides no safety or efficacy results.

Argus 15 min delay 3 alerts

+5.84% vs previous close $8.16 last price 1.8x rel. volume Open Argus

Details

Market move: IMMX +5.84% vs previous close. NEXICART-2 oral presentation

$6.85 – $8.16 Day Range

$676.49M Mkt Cap at Last Price

On Nov 4, the day this news came out, the latest delayed price for IMMX is 5.84% above the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $8.16. Relative volume is above average at 1.8x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Patients in presentation data: 45 patients

Patients in presentation data

45 patients

NXC-201 NEXICART-2 safety and efficacy data

Key Terms

car-t, breakthrough therapy designation, regenerative medicine advanced therapy, orphan drug designation

4 terms

car-t medical

"first U.S. trial of CAR-T in relapsed/refractory AL amyloidosis"

CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.

breakthrough therapy designation regulatory

"awarded Breakthrough Therapy Designation (BTD)"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

regenerative medicine advanced therapy regulatory

"Regenerative Medicine Advanced Therapy (RMAT)"

Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene, and tissue‑based therapies intended to treat serious or life‑threatening conditions; it gives developers a “fast lane” with more frequent agency interaction and eligibility for accelerated review pathways. For investors, an RMAT label signals that a therapy may reach market faster and face less regulatory uncertainty than a standard program, which can raise the potential value and reduce timeline risk—though it is not a guarantee of approval.

orphan drug designation regulatory

"Orphan Drug Designation (ODD) by FDA"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

–  Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT –

LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present an NXC-201 abstract at the upcoming American Society of Hematology (ASH) 68^th Annual Meeting and Exposition to be held December 12-15, 2026, in New Orleans, LA.

ASH Oral Presentation Details:

Event	68th ASH Annual Meeting and Exposition, New Orleans, LA
Title	“45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in relapsed/refractory AL amyloidosis”
Presentation Date/Time (Central Time)	Publication #826 Session Date: Monday, December 14, 2026 Session Name: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis Session Time: 10:30 AM -12:00 PM Presentation Time: 11:15 AM

About AL Amyloidosis
Amyloid light-chain (AL) amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains that build up in organs including the heart, kidney, and liver, causing organ failure and death. 

AL amyloidosis is the most common form of amyloidosis according to the National Institutes of Health.  The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.

The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (Immix) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains that build up in organs including the heart, kidney, and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com 

Company Contact
irteam@immixbio.com